Johnson & Johnson Talcum Powder Products

The Johnson & Johnson talcum powder docket is, by actionCount, one of the largest personal-injury mass torts in the federal system, with 69,250 actions coordinated in the District of New Jersey. Claims allege that talc-based body powder products caused ovarian cancer and, in a related claim category, mesothelioma, through long-term use. That scale alone makes this a docket where portfolio-level financing against a firm's book is a central, not incidental, part of the funding conversation.

The defining structural fact for funders to understand is that Johnson & Johnson has repeatedly attempted to resolve the bulk of these claims through a subsidiary bankruptcy strategy rather than through the ordinary civil settlement process, and bankruptcy courts have repeatedly rejected those filings, including a 2023 plan built around a roughly $9 billion proposed settlement for an estimated 50,000 claimants, on the grounds that the subsidiary was not in the financial distress bankruptcy law requires. That history means claim timing and resolution mechanics in this docket cannot be assumed to follow an ordinary mass-tort settlement calendar; a claim's path runs through whichever forum, bankruptcy or civil MDL, is live at a given moment, and that has changed more than once.

Medical-lien exposure is substantial and central to underwriting here, since ovarian cancer and mesothelioma treatment involve extensive, often ongoing oncology care, and lien resolution needs to be built into any advance or settlement-timing structure from the outset. Given the docket's scale, portfolio finance against a firm's full talc inventory is typically the more efficient structure than claim-by-claim underwriting, though pricing should explicitly account for the unresolved bankruptcy overhang rather than assume a near-term global resolution.

Criterica Capital's mass tort finance and medical-lien receivables products apply here. Given how much this docket's resolution mechanics depend on the bankruptcy litigation's trajectory, a current structural read is worth obtaining through Criterica Intelligence before sizing capital commitments.

In 2023, Johnson & Johnson proposed a global settlement of roughly $9 billion covering an estimated 50,000 claimants through its subsidiary's bankruptcy proceeding; bankruptcy judges blocked that plan on the grounds that the subsidiary was not in financial distress, and at least 38,000 lawsuits reportedly remained pending outside the bankruptcy attempt at that time.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.